Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)
March 14, 2023 11:38 AM EDTUpdated 06:50 PM
Deals

No­var­tis looks to of­fload even more of its eye prod­ucts — re­port

Katherine Lewin

News Reporter

Fol­low­ing its re­cent trend of of­fload­ing as­sets, No­var­tis is con­tact­ing po­ten­tial buy­ers for some oph­thal­mol­o­gy as­sets, Bloomberg re­port­ed Tues­day, cit­ing peo­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times